SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Purchased by Voya Investment Management LLC

Voya Investment Management LLC raised its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 9.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 796,684 shares of the company’s stock after acquiring an additional 67,559 shares during the quarter. Voya Investment Management LLC owned approximately 1.07% of SpringWorks Therapeutics worth $28,784,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Huntington National Bank lifted its stake in shares of SpringWorks Therapeutics by 38.2% in the 4th quarter. Huntington National Bank now owns 694 shares of the company’s stock valued at $25,000 after purchasing an additional 192 shares during the period. AlphaQuest LLC increased its holdings in SpringWorks Therapeutics by 70.2% in the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock valued at $36,000 after buying an additional 414 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in shares of SpringWorks Therapeutics in the fourth quarter worth about $45,000. KBC Group NV boosted its stake in shares of SpringWorks Therapeutics by 59.1% during the 4th quarter. KBC Group NV now owns 2,634 shares of the company’s stock worth $95,000 after acquiring an additional 978 shares in the last quarter. Finally, US Bancorp DE grew its position in shares of SpringWorks Therapeutics by 56.0% during the 4th quarter. US Bancorp DE now owns 4,336 shares of the company’s stock valued at $157,000 after acquiring an additional 1,556 shares during the period.

SpringWorks Therapeutics Trading Down 0.5 %

SWTX opened at $44.72 on Friday. SpringWorks Therapeutics, Inc. has a twelve month low of $28.21 and a twelve month high of $62.00. The firm has a market capitalization of $3.35 billion, a PE ratio of -12.85 and a beta of 0.79. The firm’s 50-day moving average price is $46.20 and its 200 day moving average price is $40.56.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.38). The company had revenue of $61.55 million for the quarter, compared to analyst estimates of $60.53 million. SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. As a group, analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SWTX has been the topic of a number of recent analyst reports. Wedbush reiterated an “outperform” rating and set a $81.00 price target on shares of SpringWorks Therapeutics in a research report on Thursday, February 20th. Evercore ISI boosted their price target on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Guggenheim decreased their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $74.00 target price on shares of SpringWorks Therapeutics in a research report on Friday, February 21st. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $73.20.

Insider Activity at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, CEO Saqib Islam sold 48,000 shares of SpringWorks Therapeutics stock in a transaction on Monday, February 10th. The stock was sold at an average price of $53.30, for a total value of $2,558,400.00. Following the sale, the chief executive officer now owns 1,002,502 shares in the company, valued at $53,433,356.60. The trade was a 4.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bhavesh Ashar sold 1,016 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $61.19, for a total value of $62,169.04. Following the transaction, the insider now owns 62,053 shares of the company’s stock, valued at approximately $3,797,023.07. This represents a 1.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 440,766 shares of company stock valued at $24,402,956. 7.83% of the stock is owned by company insiders.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.